Vaccinex, Inc.

Please note: The information displayed on this page might be outdated.
Vaccinex, Inc.: Vaccinex is a privately-held, clinical-stage biotechnology company. Its lead product, pepinemab, is an antibody against semaphorin 4D, a novel immunotherapy target to modulate immune response to solid tumors and chronic inflammation that drives neurodegenerative diseases. Vaccinex has an ongoing Phase 2 trial in non-small cell lung cancer (NSCLC) of pepinemab in combination with Merck KGaA’s avelumab, an immune checkpoint inhibitor, and an advanced Phase 2 trial of single agent pepinemab in Huntington’s Disease.
Based in...
US - Middle Atlantic
Public, USA
Market Cap
1895 Mt. Hope Avenue
Rochester, NY 14620
United States

Company Participants at Solebury Trout Corporate Access Calls - May 11&12

  • Maurice Zauderer, Ph.D., President & CEO

Top 10 Holders of Vaccinex, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 1.15 188,142 0.54 Funds 1/31/21
Vanguard Group, Inc. (Subfiler) 1.12 183,779 0.53 13F 12/31/20
Telemetry Investments LLC 0.46 76,000 0.22 13F 12/31/20
Oppenheimer & Co., Inc. 0.35 56,751 0.16 13F 12/31/20
Squarepoint OPS LLC 0.25 40,583 0.12 13F 12/31/20
Goldman Sachs & Co. LLC 0.22 35,204 0.10 13F 12/31/20
Citadel LP 0.21 35,094 0.10 13F 12/31/20
Northern Trust Corp. 0.10 16,502 0.05 13F 12/31/20
BlackRock Fund Advisors 0.10 16,425 0.05 13F 12/31/20
Tacita Capital, Inc. 0.08 13,574 0.04 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.